Growth Metrics

CorMedix (CRMD) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to $108.5 million.

  • CorMedix's Net Income towards Common Stockholders rose 400119.92% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.5 million, marking a year-over-year increase of 49985.95%. This contributed to the annual value of -$17.9 million for FY2024, which is 6252.03% up from last year.
  • CorMedix's Net Income towards Common Stockholders amounted to $108.5 million in Q3 2025, which was up 400119.92% from $21.9 million recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Net Income towards Common Stockholders peaked at $108.5 million during Q3 2025, and registered a low of -$14.5 million during Q1 2024.
  • In the last 5 years, CorMedix's Net Income towards Common Stockholders had a median value of $908979.0 in 2021 and averaged $6.3 million.
  • Per our database at Business Quant, CorMedix's Net Income towards Common Stockholders tumbled by 25096.04% in 2023 and then soared by 400119.92% in 2025.
  • Quarter analysis of 5 years shows CorMedix's Net Income towards Common Stockholders stood at -$7.8 million in 2021, then dropped by 5.36% to -$8.2 million in 2022, then decreased by 18.7% to -$9.7 million in 2023, then surged by 238.18% to $13.5 million in 2024, then surged by 706.07% to $108.5 million in 2025.
  • Its Net Income towards Common Stockholders was $108.5 million in Q3 2025, compared to $21.9 million in Q2 2025 and $20.6 million in Q1 2025.